Specializing In:Bioinformatics Epigenetics Immunology Data integration Data visualization
Research Interests:Prostate cancer Ovarian cancer Breast cancer
About Mark Long
Dr. Mark Long joined the faculty of the Biostatistics & Bioinformatics Department at Roswell Park Comprehensive Cancer Center as an Assistant Professor of Oncology in October 2019.
Dr. Long initially came to Roswell Park in 2009 where he received his dual Master’s degree in Biological Sciences and Systems Biology from the University at Buffalo and the University of Luxembourg (CanSys Program). He went on to complete his PhD at the University at Buffalo Roswell Park division in the Molecular Pharmacology and Cancer Therapeutics program. He continued as a postdoctoral research affiliate in the Cancer Genetics and Biostatistics & Bioinformatics departments.
In his professional career at Roswell Park, Dr. Long has utilized his training and experience to drive his own and collaborative research projects. He has an interdisciplinary skill set, with expertise in cancer biology, genomics/epigenomics, and computational approaches for the understanding and visualization of high-throughput data. He has extensive experience coding in R, as well as in the design, implementation, integration and interpretation of complex genomics data sets.
Roswell Park Comprehensive Cancer Center
- Assistant Professor of Oncology
- Biostatistics & Bioinformatics
Education and Training:
- 2011-2016 - PhD - Molecular Pharmacology & Cancer Therapeutics, State University of New York at Buffalo, Roswell Park Division, Buffalo, NY
- 2009-2011 - MS - Systems Biology, University of Luxembourg, Luxembourg, Lu
- 2009-2011 - MS - Biological Sciences, State University of New York at University at Buffalo, Roswell Park Division, Buffalo, NY
- American Association of Cancer Research (AACR)
- 2018-2019 - Post-Doctoral Research Affiliate, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 2016-2018 - Post-Doctoral Research Affiliate, Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Long MD, Jacobi JJ, Singh PK, Llimos G, Wani SA, Rowsam AM, Rosario SR, Hoogstraat M, Linder S, Kirk J, Affronti HC, Bergman A, Zwart W, Campbell MJ, Smiraglia DJ. Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer. Cell Rep. 2021 Dec 14;37(11):110109.
Oba T, Long MD*, Keler T, Marsh HC, Minderman H, Abrams SI, Liu S, Ito F. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat Commun. 2020 Oct 27;11(1):5415. * Co-lead author.
Zhou Y, Bastian IN, Long MD*, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):e2025840118. * Co-lead author.
Long MD, Dhiman VK, Affronti HC, Hu Q, Liu S, Smiraglia DJ. Dynamic patterns of DNA methylation in the normal prostate epithelial differentiation program are targets of aberrant methylation in prostate cancer. Sci Rep. 2021 Jun 1;11(1):11405.
Long MD, Singh PK, Russell J, Llimos G, Rosario SR, Rizvi A, van den Berg PR, Kirk J, Sucheston-Campbell LE, Smiraglia DJ, Campbell MJ. The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression. Oncogene. 2019 Jan;38(3):421-444.